LEGAL ALERT: FDA resumes domestic surveillance inspections (RAPS)

Editor's Note

The U.S. Food and Drug Administration (FDA) announced that domestic inspections (including food and dietary supplements) would resume this week. In communication with the Regulatory Affairs Professionals Society newsletter, the agency stated that declining COVID-19 case rates would allow a return to routine surveillance inspections. FDA had temporarily halted all but mission-critical domestic and foreign inspections during a rise in case rates and the spread of the omicron variant in late December. The agency stated that foreign inspections would also be resumed based on CDC travel recommendations and individual country clearances.

February 4, 2022

RAPS

FDA resumes domestic surveillance inspections

Citing declining COVID-19 cases, a US Food and Drug Administration (FDA) spokesperson told Focus that the agency will resume its domestic surveillance inspection operations on 7 February 2022.

In emailed comments to Focus, Shelly Burgess, senior media advisor within FDA’s Office of Regulatory Affairs, said the agency decided on 2 February to resume the inspections following the extended halt the agency announced last month. “Beginning on Feb. 7, the agency will resume conducting domestic surveillance inspections across all commodities given the decline in COVID-19 cases across the country,” she said.